Irbesartan is an angiotensin ii receptor blocker used to treat high blood pressure. It works by blocking the action of angiotensin ii which prevents vasoconstriction and lowers blood pressure. By inhibiting this receptor it promotes relaxation of arterial walls. This leads to reduced systemic vascular resistance and improved blood flow. The drug does not affect heart rate or cardiac contractility directly. Its pharmacologic effect is primarily due to antagonism at the type 1 at1 subtype of angiotensin ii receptors.

Irbesartan is an angiotensin ii receptor blocker used primarily to treat high blood pressure and to protect the kidneys in patients with type 2 diabetes. It works by selectively binding to the at1 receptor, preventing angiotensin ii from causing blood vessel tightening. This blockade leads to relaxation of vascular smooth muscle and a reduction in peripheral resistance. The resulting decrease in blood pressure improves overall cardiovascular function. By reducing aldosterone mediated sodium retention, Irbesartan also helps lower fluid volume and pressure. These combined actions make it effective for long term control of hypertension and for slowing progression of diabetic kidney disease.

Darkening of the skin may occur in areas exposed to sunlight. Increased oiliness of the skin is often reported. Dryness or mild itching can be experienced. Headache and fatigue are commonly reported systemic effects. Gastrointestinal disturbances such as nausea may appear. Muscle aches and joint pain are also noted frequently.

Many treatments may cause mild fatigue. Headache is frequently reported. Nausea often appears early. Dizziness can occur intermittently. Skin irritation may develop at application sites. Sleep disturbances are occasionally noted.